Literature DB >> 24256550

Diode laser photocoagulation for retinopathy of prematurity: outcomes after 7 years of treatment.

Simona-Delia Nicoara, Cristina Cristian, Iulian Irimescu, Anne-Claudia Stefanut, Gabriela Zaharie.   

Abstract

PURPOSE: This study aimed to evaluate the outcome of transpupillary diode laser photocoagulation for retinopathy of prematurity (ROP) at one institution in Romania.
METHODS: This retrospective case series included all infants who received indirect diode laser photocoagulation for ROP between January 1, 2006, and December 31, 2012.
RESULTS: The 160 eyes of 83 infants were classified into two categories: 136 eyes (85%) with classic disease (stage III ROP in zones 1 or 2) and 24 eyes (15%) with aggressive posterior ROP (AP-ROP). ROP regressed in 141 eyes (88.12%). The success rate was significantly better in the classic ROP group (94.11%) compared to the AP-ROP group (54.16%) (P < .001).
CONCLUSIONS: The ROP regression rate after the laser treatment was 88% in this series. Copyright 2014, SLACK Incorporated.

Entities:  

Mesh:

Year:  2013        PMID: 24256550     DOI: 10.3928/01913913-20131112-02

Source DB:  PubMed          Journal:  J Pediatr Ophthalmol Strabismus        ISSN: 0191-3913            Impact factor:   1.402


  9 in total

1.  One-year clinical outcome after laser treatment for retinopathy of prematurity at a tertiary center in Turkey.

Authors:  Murat Gunay; Gokhan Celik; Fahri Ovali; Huseyin Yetik; Alev Aktas; Betul Onal Gunay
Journal:  Int Ophthalmol       Date:  2014-11-09       Impact factor: 2.031

2.  Factors associated with refractive outcome in children treated with bevacizumab for retinopathy of prematurity: the importance of retinal vascularization.

Authors:  Sadik Etka Bayramoglu; Nihat Sayin
Journal:  Int Ophthalmol       Date:  2022-05-17       Impact factor: 2.029

3.  Resveratrol, an Inhibitor Binding to VEGF, Restores the Pathology of Abnormal Angiogenesis in Retinopathy of Prematurity (ROP) in Mice: Application by Intravitreal and Topical Instillation.

Authors:  Wei-Hui Hu; Xiao-Yong Zhang; Ka-Wing Leung; Ran Duan; Ting-Xia Tina Dong; Qi-Wei Qin; Karl Wah-Keung Tsim
Journal:  Int J Mol Sci       Date:  2022-06-09       Impact factor: 6.208

Review 4.  The role of anti-vascular endothelial growth factor in treatment of retinopathy of prematurity-a current review.

Authors:  Shing Chuen Chow; Pun Yuet Lam; Wai Ching Lam; Nicholas Siu Kay Fung
Journal:  Eye (Lond)       Date:  2022-01-11       Impact factor: 4.456

5.  Time at treatment of severe retinopathy of prematurity in China: recommendations for guidelines in more mature infants.

Authors:  Yi Chen; Jing Feng; Clare Gilbert; Hong Yin; Jianhong Liang; Xiaoxin Li
Journal:  PLoS One       Date:  2015-02-09       Impact factor: 3.240

6.  Outcomes and Prognostic Factors of Intravitreal Bevacizumab Monotherapy in Zone I Stage 3+ and Aggressive Posterior Retinopathy of Prematurity.

Authors:  Simona Delia Nicoară; Constanța Nascutzy; Cristina Cristian; Iulian Irimescu; Anne Claudia Ștefănuț; Gabriela Zaharie; Tudor Drugan
Journal:  J Ophthalmol       Date:  2015-09-27       Impact factor: 1.909

7.  Regression Rates Following the Treatment of Aggressive Posterior Retinopathy of Prematurity with Bevacizumab Versus Laser: 8-Year Retrospective Analysis.

Authors:  Simona D Nicoară; Anne C Ștefănuţ; Constanta Nascutzy; Gabriela C Zaharie; Laura E Toader; Tudor C Drugan
Journal:  Med Sci Monit       Date:  2016-04-10

8.  Intravitreal bevacizumab as rescue therapy following treatment failure with laser photocoagulation in retinopathy of prematurity.

Authors:  Caner Kara; Emre Hekimoğlu; İkbal Seza Petriçli; Handan Akıl
Journal:  J Curr Ophthalmol       Date:  2017-08-24

9.  A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity.

Authors:  Yong Cheng; Qingyu Meng; Dandan Linghu; Mingwei Zhao; Jianhong Liang
Journal:  Sci Rep       Date:  2018-07-16       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.